{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:51:41Z","timestamp":1781635901408,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF22OC0071681"],"award-info":[{"award-number":["NNF22OC0071681"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU Horizon Europe Program grant miGut-Health: personalized blueprint of intestinal health","award":["101095470"],"award-info":[{"award-number":["101095470"]}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF20OC0059377"],"award-info":[{"award-number":["NNF20OC0059377"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>As a result of an aging population and the rising incidence of inflammatory bowel diseases (IBD) across all age groups, more patients with IBD are being diagnosed with cancer both before and after their IBD diagnosis. We describe the treatment of patients with IBD with prior or coexisting cancer relative to patients with IBD and no cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Danish national registers were used to identify incident and prevalent patients with IBD, drug exposure, and cancer status, from 1996 to 2022. Cox regressions were used to compare medications and the risk of surgery among patients with and without cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total 59\u2009494 patients with IBD (20\u2009551 Crohn\u2019s disease [CD; 34.5%], 38\u2009943 ulcerative colitis [UC; 65.5%]) were included. Of those, 2675 (4.5%) had been diagnosed with cancer prior to IBD. Of the remaining 56\u2009819 patients with IBD, 6636 (11.7%) had their first cancer develop after their IBD diagnosis. Prior cancer was associated with reduced immunomodulator use for CD and UC, and increased anti-tumor necrosis factor (anti-TNF) use in UC. Furthermore, patients with CD and UC and a history of cancer had an increased risk of undergoing IBD-related surgery during follow-up. Patients who developed cancer during the course of their IBD largely had their anti-TNF and immunomodulator therapy discontinued following a cancer diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with IBD and prior or coexisting cancer were treated differently from patients with no history of cancer. We observed greater caution around initiating immunosuppressants for patients with prior cancer, while more patients required IBD-related surgery. Greater caution was observed around reinitiating immunosuppressants for patients diagnosed with cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag073","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:47:43Z","timestamp":1779277663000},"source":"Crossref","is-referenced-by-count":0,"title":["Medical and surgical therapies for patients with inflammatory bowel diseases and prior or coexisting cancer: a Danish nationwide cohort study"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8055-9899","authenticated-orcid":false,"given":"Jonathan","family":"Plovgaard","sequence":"first","affiliation":[{"name":"Gastro Unit, Medical Division, Hvidovre Hospital, University of Copenhagen , Hvidovre,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital , Hvidovre,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Damsgaard","family":"Wewer","sequence":"additional","affiliation":[{"name":"Gastro Unit, Medical Division, Hvidovre Hospital, University of Copenhagen , Hvidovre,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital , Hvidovre,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Bendtsen","sequence":"additional","affiliation":[{"name":"Gastro Unit, Medical Division, Hvidovre Hospital, University of Copenhagen , Hvidovre,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital , Hvidovre,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[{"name":"Gastro Unit, Medical Division, Hvidovre Hospital, University of Copenhagen , Hvidovre,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital , Hvidovre,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026061613535501000_jjag073-B1","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1002\/1878-0261.13302","article-title":"The role of aging in cancer","volume":"16","author":"Havas","year":"2022","journal-title":"Mol Oncol"},{"key":"2026061613535501000_jjag073-B2","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x","article-title":"Increased risk of intestinal cancer in Crohn\u2019s disease: A meta-analysis of population-based cohort studies","volume":"100","author":"Jess","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"2026061613535501000_jjag073-B3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026061613535501000_jjag073-B4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cgh.2020.08.015","article-title":"The risk of extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies","volume":"19","author":"Lo","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026061613535501000_jjag073-B5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/pds.3621","article-title":"Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies","volume":"23","author":"Beigel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026061613535501000_jjag073-B6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"2026061613535501000_jjag073-B7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026061613535501000_jjag073-B8","doi-asserted-by":"publisher","first-page":"i2064","DOI":"10.1093\/ecco-jcc\/jjad212.1296","article-title":"Thiopurines and risk of cancer in patients with inflammatory bowel disease - a Danish nationwide cohort study 1996-2018","volume":"18","author":"Wewer","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026061613535501000_jjag073-B9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jgh.14533","article-title":"Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"34","author":"Huang","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"2026061613535501000_jjag073-B10","doi-asserted-by":"publisher","first-page":"jjaf091","DOI":"10.1093\/ecco-jcc\/jjaf091","article-title":"Cancer incidence in patients with ulcerative colitis na\u00efve to or treated with thiopurine and targeted therapies\u2014a cohort study 2007 to 2022 with comparison to the general population","volume":"19","author":"Everhov","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026061613535501000_jjag073-B11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"2026061613535501000_jjag073-B12","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026061613535501000_jjag073-B13","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2026061613535501000_jjag073-B14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026061613535501000_jjag073-B15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/j.gastro.2022.07.062","article-title":"The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study","volume":"163","author":"Agrawal","year":"2022","journal-title":"Gastroenterology"},{"key":"2026061613535501000_jjag073-B16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/apt.13971","article-title":"The incidence of inflammatory bowel disease in Denmark 1980\u20132013: a nationwide cohort study","volume":"45","author":"Lophaven","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061613535501000_jjag073-B17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on inflammatory bowel disease and malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026061613535501000_jjag073-B18","first-page":"A07220458","article-title":"Identifying patients with inflammatory bowel disease in the Danish National Patient Register","volume":"70","author":"Lo","year":"2023","journal-title":"Dan Med J"},{"key":"2026061613535501000_jjag073-B19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.18106","article-title":"Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent \u2013 Results from a Danish nationwide cohort study, 2000\u20132018","volume":"60","author":"Nordestgaard","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061613535501000_jjag073-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.crohns.2013.10.006","article-title":"Differences in the management of pediatric and adult onset ulcerative colitis - lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2026061613535501000_jjag073-B21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand J Public Health"},{"key":"2026061613535501000_jjag073-B22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag073\/68536036\/jjag073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag073\/68536036\/jjag073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:02Z","timestamp":1781632442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag073\/8709115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag073","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"jjag073"}}